Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.

Brown JD, Adams VR, Moga DC.

Healthcare (Basel). 2016 Dec 20;4(4). pii: E93. doi: 10.3390/healthcare4040093.

2.

The relationship between anemia and recurrence of ischemic stroke in patients with Trousseau's syndrome: A retrospective cross-sectional study.

Yigit M, Sogut O, Yigit E, Turkdogan KA, Kaplan O, Dur A, Sonmez E, Demirel B.

Turk J Emerg Med. 2016 May 9;16(2):65-68.

4.
5.

Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.

Ashrani AA, Gullerud RE, Petterson TM, Marks RS, Bailey KR, Heit JA.

Thromb Res. 2016 Mar;139:29-37. doi: 10.1016/j.thromres.2016.01.002.

PMID:
26916293
6.

Vitamin C and functional iron deficiency anemia in hemodialysis.

Kim YL.

Kidney Res Clin Pract. 2012 Mar;31(1):1-3. doi: 10.1016/j.krcp.2011.12.008. No abstract available.

7.

Impact of a Patient Blood Management Program and an Outpatient Anemia Management Protocol on Red Cell Transfusions in Oncology Inpatients and Outpatients.

Gross I, Trentino KM, Andreescu A, Pierson R, Maietta RA, Farmer S.

Oncologist. 2016 Mar;21(3):327-32. doi: 10.1634/theoncologist.2015-0406.

PMID:
26865590
8.

On random-effects meta-analysis.

Zeng D, Lin DY.

Biometrika. 2015 Jun;102(2):281-294.

9.

Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Rainville N, Jachimowicz E, Wojchowski DM.

Expert Opin Ther Targets. 2016;20(3):287-301. doi: 10.1517/14728222.2016.1090975. Review.

PMID:
26419263
10.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J.

Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9.

11.

Low Oxygen Tension Primes Aortic Endothelial Cells to the Reparative Effect of Tissue-protective Cytokines.

Heikal L, Ghezzi P, Mengozzi M, Ferns G.

Mol Med. 2015 Sep 1. doi: 10.2119/molmed.2015.00162. [Epub ahead of print]

12.

Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials.

Zhao Q, Hong D, Zhang Y, Sang Y, Yang Z, Zhang X.

Medicine (Baltimore). 2015 Apr;94(14):e731. doi: 10.1097/MD.0000000000000731.

13.

Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.

Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H, Shi J, De Domenico I, Tricot G, Zhan F.

Cancer Res. 2015 Jun 1;75(11):2211-21. doi: 10.1158/0008-5472.CAN-14-3804.

14.

Epoetin beta for the treatment of chemotherapy-induced anemia: an update.

Galli L, Ricci C, Egan CG.

Onco Targets Ther. 2015 Mar 5;8:583-91. doi: 10.2147/OTT.S77497. Review.

15.
16.

Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device.

Nassif ME, Patel JS, Shuster JE, Raymer DS, Jackups R Jr, Novak E, Gage BF, Prasad S, Silvestry SC, Ewald GA, LaRue SJ.

JACC Heart Fail. 2015 Feb;3(2):146-53. doi: 10.1016/j.jchf.2014.08.005.

17.

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Izzedine H, Perazella MA.

Nephrol Dial Transplant. 2015 Dec;30(12):1979-88. doi: 10.1093/ndt/gfu387. Review.

18.

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Hendrick F, Davidoff AJ, Zeidan AM, Gore SD, Baer MR.

Medicare Medicaid Res Rev. 2014 Nov 26;4(4). pii: mmrr2014-004-04-a02. doi: 10.5600/mmrr.004.04.a02. Erratum in: Medicare Medicaid Res Rev. 2014;4(4). pii: mmrr2014-004-04-a02_corrigendum.

19.

Clinicaltrials.gov: Is the Glass Half Full?

Guharoy V.

Hosp Pharm. 2014 Nov;49(10):893-5. doi: 10.1310/hpj4910-893. No abstract available.

20.

Regulatory and clinical considerations for biosimilar oncology drugs.

Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL, Noxon V, Bobolts L, Armitage M, Bian J, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO.

Lancet Oncol. 2014 Dec;15(13):e594-605. doi: 10.1016/S1470-2045(14)70365-1. Review.

Items per page

Supplemental Content

Support Center